6335-03-1

Usage

InChI:InChI=1/C12H11NO2/c1-8(2)7-13-11(14)9-5-3-4-6-10(9)12(13)15/h3-6H,1,7H2,2H3

Upstream product

• 85-44-9 phthalic anhydride 
• 2878-14-0 2-methylallylamin 

Downstream Products

• 133787-11-8 α-N-benzoyl-γ-methyl-δ-N-phthaloylornithine methyl ester 
• 1097625-01-8 2-[2-methyl-3-(2,3,4,9-tetrahydro-1H-β-carbolin-1-yl)-propyl]-isoindole-1,3-dione 
• 6649-77-0 1-(2-methyl-propyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole 
• 775354-82-0 benzyl-bis-[4-(isoindol-1,3-dione)-3-methylbutyl]-amine 
• 775354-86-4 p-methoxybenzyl-bis[4-(N-phthalimidyl)-3-methylbutyl]amine 
• 775354-90-0 {[p-methoxybenzyl-({bis-[4-(N-phthalimidyl)-3-methyl-butyl]amino}methyl-butyl)amino]methyl-butyl}-bis[4-(N-phthalimidyl)-3-methylbutyl]amine 
• 41764-18-5 4-methyl-3,4-dihydro-2H-benzo[c]azepine-1,5-dione 

Relevant academic research and scientific papers

NEW CHEMICAL COMPOUNDS

The present invention encompasses compounds of general formula (1) while the groups R4 to R7 and the units W, L, Qa and QH are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use as medicaments having the above-mentioned properties.

NEW CHEMICAL COMPOUNDS

The present invention encompasses compounds of general formula (1) wherein the units W, A, L, Q1 and QH are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use as medicaments having the above-mentioned properties.

Isomerization of N-Allylamides and -imides to Aliphatic Enamides by Iron, Rhodium, and Ruthenium Complexes

Substituted aliphatic N-propenylamides and -imides are readily sythesized from N-allylamides by double bond migration induced by rhodium or ruthenium hydrides.N-Propenylimides can be prepared from allylimides only in the presence of iron pentacarbonyl.